Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
M A PowellL BjørgeL WillmottZ NovákD BlackL GilbertS SharmaG ValabregaL M LandrumM Gropp-MeierA StuckeyI BoereM A GoldY SegevS E GillC GennigensA SebastianelliM S ShahinB PothuriB J MonkJ BuscemaR L ColemanB M SlomovitzK L RingT J HerzogM M BalasM GrimshawS StevensD W LaiC McCourtM R MirzaPublished in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)
Dostarlimab in combination with carboplatin-paclitaxel demonstrated a statistically significant and clinically meaningful OS benefit in the overall population of patients with primary advanced or recurrent EC while demonstrating an acceptable safety profile.